Literature DB >> 28781505

Cancer Immunotherapy, Part 3: Challenges and Future Trends.

C Lee Ventola.   

Abstract

Despite dramatic breakthroughs, obstacles remain for the field of immunotherapy in cancer. These include the inability to predict treatment efficacy and patient response; the need for improved biomarkers; the development of resistance to immunotherapies; the lack of optimized clinical study designs; and high costs. Are solutions in sight?

Entities:  

Year:  2017        PMID： 28781505      PMCID： PMC5521300     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  33 in total

Review 1.  Molecular prescreening to select patient population in early clinical trials.

Authors:  Jordi Rodón; Cristina Saura; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; José Baselga; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

2.  A new era in cancer immunotherapy: discovering novel targets and reprogramming the immune system.

Authors:  Maurizio Chiriva-Internati; Adrian Bot
Journal:  Int Rev Immunol       Date:  2015-03       Impact factor: 5.311

Review 3.  A personalized view on cancer immunotherapy.

Authors:  Laura Wayteck; Karine Breckpot; Jo Demeester; Stefaan C De Smedt; Koen Raemdonck
Journal:  Cancer Lett       Date:  2013-09-17       Impact factor: 8.679

Review 4.  Current Challenges in Cancer Treatment.

Authors:  Jon Zugazagoitia; Cristiano Guedes; Santiago Ponce; Irene Ferrer; Sonia Molina-Pinelo; Luis Paz-Ares
Journal:  Clin Ther       Date:  2016-05-02       Impact factor: 3.393

Review 5.  Immunotherapy Approaches in Cancer Treatment.

Authors:  Pavel Klener; Pavel Otáhal; Lucie Lateckova; Pavel Klener
Journal:  Curr Pharm Biotechnol       Date:  2015       Impact factor: 2.837

Review 6.  Cancer immunotherapy: harnessing the immune system to battle cancer.

Authors:  Yiping Yang
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 7.  Cancer immunoprevention.

Authors:  Olivera J Finn; Pamela L Beatty
Journal:  Curr Opin Immunol       Date:  2016-01-19       Impact factor: 7.486

8.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors:  Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

Review 9.  New approaches for cancer immunotherapy.

Authors:  Ayfer Karlitepe; Ozgun Ozalp; Cigir Biray Avci
Journal:  Tumour Biol       Date:  2015-05-02

Review 10.  Next-generation sequencing to guide cancer therapy.

Authors:  Jeffrey Gagan; Eliezer M Van Allen
Journal:  Genome Med       Date:  2015-07-29       Impact factor: 11.117
View more
  77 in total

1.  MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma.

Authors:  Yufeng Lv; Zhong Huang; Yan Lin; Yuan Fang; Zhichao Chen; Lili Pan; Yanxian Zhang; Zihai Xu
Journal:  Oncoimmunology       Date:  2019-06-24       Impact factor: 8.110

2.  GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.

Authors:  Sonia Brun; Firas Bassissi; Cindy Serdjebi; Marie Novello; Jennifer Tracz; François Autelitano; Marie Guillemot; Philippe Fabre; Jérôme Courcambeck; Christelle Ansaldi; Eric Raymond; Philipe Halfon
Journal:  Invest New Drugs       Date:  2019-02-19       Impact factor: 3.850

Review 3.  Genomics-Guided Immunotherapy for Precision Medicine in Cancer.

Authors:  Shradha Mukherjee
Journal:  Cancer Biother Radiopharm       Date:  2019-07-16       Impact factor: 3.099

Review 4.  Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study.

Authors:  Syafiq Ramlee; David Hulse; Kinga Bernatowicz; Raquel Pérez-López; Evis Sala; Luigi Aloj
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

Review 5.  Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.

Authors:  Piper A Rawding; Jiyoon Bu; Jianxin Wang; Da Won Kim; Adam J Drelich; Youngsoo Kim; Seungpyo Hong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-08-19

6.  An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy.

Authors:  Jiyoon Bu; Ashita Nair; Mari Iida; Woo-Jin Jeong; Michael J Poellmann; Kara Mudd; Luke J Kubiatowicz; Elizabeth W Liu; Deric L Wheeler; Seungpyo Hong
Journal:  Nano Lett       Date:  2020-06-11       Impact factor: 11.189

7.  Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy.

Authors:  Lauren Dennison; Amanda Ruggieri; Aditya Mohan; James Leatherman; Kayla Cruz; Skylar Woolman; Nilofer Azad; Gregory B Lesinski; Elizabeth M Jaffee; Mark Yarchoan
Journal:  Cancer Immunol Res       Date:  2021-08-13       Impact factor: 11.151

Review 8.  Microfluidic technologies for immunotherapy studies on solid tumours.

Authors:  K Paterson; S Zanivan; R Glasspool; S B Coffelt; M Zagnoni
Journal:  Lab Chip       Date:  2021-06-15       Impact factor: 6.799

9.  Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade.

Authors:  Yu Saida; Jeffrey R Brender; Kazutoshi Yamamoto; James B Mitchell; Murali C Krishna; Shun Kishimoto
Journal:  Cancer Res       Date:  2021-04-09       Impact factor: 13.312

10.  Inorganic Nanomaterial-Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities.

Authors:  Guanyou Lin; Richard A Revia; Miqin Zhang
Journal:  Adv Funct Mater       Date:  2020-10-13       Impact factor: 18.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.